Our Pipeline

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

Print PDF
Program Phase 1 Phase 2 Phase 3
BRENTUXIMAB VEDOTIN1
DescriptionCD30 Antibody Drug Conjugate Disease(s) under investigationHodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma
Click here to search clinical trials
BRIGATINIB
DescriptionALK Inhibitor Disease(s) under investigationNon-small Cell Lung Cancer
Click here to search clinical trials
IXAZOMIB
DescriptionProteasome Inhibitor Disease(s) under investigationMultiple Myeloma, Amyloidosis
Click here to search clinical trials
PEVONEDISTAT
DescriptionNedd8-Activating Enzyme Inhibitor Disease(s) under investigationHigh-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia
Click here to search clinical trials
DescriptionNedd8-Activating Enzyme Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
PONATINIB2
DescriptionBCR-ABL Inhibitor Disease(s) under investigationChronic Myeloid Leukemia
Click here to search clinical trials
DescriptionBCR-ABL Inhibitor Disease(s) under investigationPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
Click here to search clinical trials
SAPANISERTIB (TAK-228)
DescriptionTORC1/TORC2 Inhibitor Disease(s) under investigationEndometrial Cancer
Click here to search clinical trials
DescriptionTORC1/TORC2 Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
TAK-659
DescriptionSYK/FLT-3 Inhibitor Disease(s) under investigationLymphoma, Acute Myelogenous Leukemia
Click here to search clinical trials
DescriptionSYK/FLT-3 Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
TAK-931
DescriptionCDC7 Inhibitor Disease(s) under investigationPancreatic Cancer, Colorectal Cancer
Click here to search clinical trials
DescriptionCDC7 Inhibitor Disease(s) under investigationSolid Tumors
Click here to search clinical trials
CABOZANTINIB3
DescriptionMET, VEGF, AXL and RET Inhibitor Disease(s) under investigationRenal Cell Carcinoma
Click here to search clinical trials
VEDOLIZUMAB
DescriptionAnti-α4β7 Antibody Disease(s) under investigationGraft versus Host Disease
Click here to search clinical trials
NIRAPARIB4
DescriptionPARP Inhibitor Disease(s) under investigationOvarian Cancer
Click here to search clinical trials
TAK-522 (XMT-1522)5
DescriptionHER2 Dolaflexin Antibody Drug Conjugate Disease(s) under investigationBreast Cancer
Click here to search clinical trials
TAK-788 (AP32788)
DescriptionEGFR/HER2 Inhibitor Disease(s) under investigationNon-small Cell Lung Cancer
Click here to search clinical trials
TAK-573
DescriptionCD38-targeted IgG4 fused with attenuated IFNα Disease(s) under investigationMultiple Myeloma
Click here to search clinical trials
TAK-164
DescriptionAnti-guanylyl cyclase C antibody drug conjugate Disease(s) under investigationPancreatic Cancer, Colorectal Cancer
Click here to search clinical trials
Print PDF

Last updated 2018-05-10

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 3 Japan Only. 4 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. 5 Ex-Us, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc.